Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and 18F-FDG using a combined PET/MR scanner

Atherosclerosis

Volumn 228, Issue 2, 2013, Pages 339-345

  Millon, A ^a   Dickson, S D ^a   Klink, A ^a   Izquierdo Garcia, D ^a   Bini, J ^a   Lancelot, E ^b   Ballet, S ^b   Robert, P ^b   Mateo de Castro, J ^a   Corot, C ^b   Fayad, Z A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Laboratoire Guerbet   (France)

Author keywords

Animal experimentations; Imaging; Inflammation; MRI; PET; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUORODEOXYGLUCOSE F 18; P 904; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERITIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL DENSITY; CHOLESTEROL DIET; CONTRAST ENHANCEMENT; CONTROLLED STUDY; COURSE EVALUATION; DRUG UPTAKE; IMAGE ANALYSIS; IMAGE PROCESSING; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREND STUDY;

ANIMALS; AORTA, ABDOMINAL; AORTIC DISEASES; ATHEROSCLEROSIS; CONTRAST MEDIA; DEXTRANS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PYRROLES; RABBITS; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 84878110892     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.03.019     Document Type: Article

References (32)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.
2. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
3. Sukhova G.K., Williams J.K., Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002, 22:1452-1458.
4. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105:2708-2711.
5. Tang T.Y., Muller K.H., Graves M.J., et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 2009, 29:1001-1008.
6. Sigovan M., Boussel L., Sulaiman A., et al. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model. Radiology 2009, 252:401-409.
7. Tang T.Y., Howarth S.P., Miller S.R., et al. The ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. JAm Coll Cardiol 2009, 53:2039-2050.
8. Tawakol A., Fayad Z.A., Mogg R., et al. High dose statin results in a further reduction in atherosclerotic inflammation compared with low dose statin: results of a Multi-Center PET-CT study. Circulation 2011, 124. Abstract 18242.
9. Kooi M.E., Cappendijk V.C., Cleutjens K.B., et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by invivo magnetic resonance imaging. Circulation 2003, 107:2453-2458.
10. Tang T.Y., Howarth S.P., Miller S.R., et al. Correlation of carotid atheromatous plaque inflammation using USPIO-enhanced MR imaging with degree of luminal stenosis. Stroke 2008, 39:2144-2147.
11. Trivedi R.A., Mallawarachi C., King-Im J.M.U., et al. Identifying inflamed carotid plaques using invivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006, 26:1601-1606.
12. te Boekhorst B.C., Bovens S.M., Nederhoff M.G., et al. Negative MR contrast caused by USPIO uptake in lymph nodes may lead to false positive observations with invivo visualization of murine atherosclerotic plaque. Atherosclerosis 2010, 210:122-129.
13. Briley-Saebo K.C., Mani V., Hyafil F., Cornily J.C., Fayad Z.A. Fractionated Feridex and positive contrast: invivo MR imaging of atherosclerosis. Magn Reson Med 2008, 59:721-730.
14. Sigovan M., Bessaad A., Alsaid H., et al. Assessment of age modulated vascular inflammation in ApoE-/- mice by USPIO-enhanced magnetic resonance imaging. Invest Radiol 2010, 45:702-707.
15. Kuhlpeter R., Dahnke H., Matuszewski L., et al. R2 and R2* mapping for sensing cell-bound superparamagnetic nanoparticles: invitro and murine invivo testing. Radiology 2007, 245:449-457.
16. Zhou G., Ge S., Liu D., et al. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology 2010, 115:221-228.
17. Worthley S.G., Zhang Z.Y., Machac J., et al. Invivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiovasc Imaging 2009, 25:251-257.
18. Vucic E., Dickson S.D., Calcagno C., et al. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging 2011, 4:1100-1109.
19. Wu Y.W., Kao H.L., Huang C.L., et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 2012, 39:399-407.
20. Rudd J.H., Myers K.S., Bansilal S., et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. JNucl Med 2008, 49:871-878.
21. Izquierdo-Garcia D., Davies J.R., Graves M.J., et al. Comparison of methods for magnetic resonance-guided [18-F] fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods. Stroke 2009, 40:86-93.
22. Lobatto M.E., Calcagno C., Metselaar J.M., et al. Imaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging. Methods Enzymol 2012, 508:211-228.
23. Derlin T., Habermann C.R., Hahne J.D., et al. Quantification of [18F]-FDG uptake in atherosclerotic plaque: impact of renal function. Ann Nucl Med 2011, 25:586-591.
24. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. JAm Coll Cardiol 2006, 48:1825-1831.
25. Puato M., Faggin E., Rattazzi M., et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. Stroke 2010, 41:1163-1168.
26. Riedmüller K., Metz S., Bonaterra G.A., et al. Cholesterol diet and effect of long-term withdrawal on plaque development and composition in the thoracic aorta of New Zealand white rabbits. Atherosclerosis 2010, 210:407-413.
27. Folco E.J., Sheikine Y., Rocha V.Z., et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. JAm Coll Cardiol 2011, 58:603-614.
28. Calcagno C., Cornily J.C., Hyafil F., et al. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol 2008, 28:1311-1317.
29. Amirbekian V., Lipinski M.J., Briley-Saebo K.C., et al. Detecting and assessing macrophages invivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104:961-966.
30. Briley-Saebo K.C., Cho Y.S., Shaw P.X., et al. Targeted iron oxide particles for invivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. JAm Coll Cardiol 2011, 57:337-347.
31. Ouimet T., Lancelot E., Hyafil F., et al. Molecular and cellular targets of the MRI contrast agent p947 for atherosclerosis imaging. Mol Pharm 2012, 9:850-861.
32. Hyafil F., Vucic E., Cornily J.C., et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. Eur Heart J 2011, 32:1561-1571.